首页> 外文OA文献 >Role of CD4+ and CD8+ T-Cell Responses against JC Virus in the Outcome of Patients with Progressive Multifocal Leukoencephalopathy (PML) and PML with Immune Reconstitution Inflammatory Syndrome ▿
【2h】

Role of CD4+ and CD8+ T-Cell Responses against JC Virus in the Outcome of Patients with Progressive Multifocal Leukoencephalopathy (PML) and PML with Immune Reconstitution Inflammatory Syndrome ▿

机译:抗JC病毒的CD4 +和CD8 + T细胞反应在进行性多灶性白细胞性脑病(PML)和PML合并免疫重建炎性综合征的患者预后中的作用 ▿

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the brain caused by JC virus (JCV). To assess the role of CD4+ and CD8+ T-cells against JCV in the clinical outcome of PML and PML in the setting of immune reconstitution inflammatory syndrome (IRIS), we tested gamma interferon (IFN-γ) response by enzyme-linked immunosorbent spot (ELISpot) and intracellular cytokine staining (ICS) in 117 subjects, including 66 PML patients with different clinical outcomes. Both assays were concordant and demonstrated that the cellular immune response against JCV is associated with better clinical outcome. PML survivors had an early CD8+ T-cell response more frequently than PML progressors (100% versus 27.3%; P = 0.001), while only a trend was observed for the early CD4+ T-cell response between these two groups (80% versus 45.5%; P = 0.18). Although IRIS itself was more frequent in the PML survivor group, there was no difference in IFN-γ-producing CD4+ and CD8+ T-cells between IRIS and non-IRIS PML patients, suggesting that T-cells expressing other cytokines likely have a role in the immunopathogenesis of IRIS. ELISpot and ICS assays are useful prognostic markers of PML evolution and may help in the clinical management of these patients.
机译:进行性多灶性白质脑病(PML)是由JC病毒(JCV)引起的严重的大脑脱髓鞘疾病。为了评估针对JCV的CD4 +和CD8 + T细胞在PML和PML在免疫重建性炎症综合症(IRIS)的临床结果中的作用,我们通过酶联免疫吸附剂检测了γ干扰素(IFN-γ)的反应( ELISpot)和细胞内细胞因子染色(ICS)在117位受试者中进行,其中包括66位具有不同临床结局的PML患者。两种测定结果一致,证明针对JCV的细胞免疫反应与更好的临床结果相关。 PML幸存者对CD8 + T细胞的早期反应比PML进展者更为频繁(100%对27.3%; P = 0.001),而在这两组之间仅观察到CD4 + T细胞早期反应的趋势(80%对45.5) %; P = 0.18)。尽管IRIS本身在PML幸存者组中更为频繁,但IRIS和非IRIS PML患者之间产生IFN-γ的CD4 +和CD8 + T细胞没有差异,这表明表达其他细胞因子的T细胞可能在IRIS的免疫发病机制。 ELISpot和ICS分析是PML演变的有用预后标志物,可能有助于这些患者的临床治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号